Feng Chi Biotech Corp. (TPEX:6744)

Market Cap	257.18M -15.2%
Revenue (ttm)	177.36M +3.7%
Net Income	14.47M -12.8%
EPS	0.94 -12.2%
Shares Out	15.40M
PE Ratio	17.77
Forward PE	n/a
Dividend	0.95 (5.69%)
Ex-Dividend Date	Jul 22, 2025

Volume	26,409
Average Volume	60,576
Open	16.30
Previous Close	16.80
Day's Range	16.30 - 17.20
52-Week Range	13.30 - 22.10
Beta	0.23
RSI	52.90
Earnings Date	Apr 30, 2026

About Feng Chi Biotech

Feng Chi Biotech Corp. engages in the wholesale and retail of medical equipment and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services. It also distributes various genetic testing technologies and products in oncology. The company was founded in 1992 and is based in Taipei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 32
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6744

Financial Performance

In 2025, Feng Chi Biotech's revenue was 177.36 million, an increase of 3.66% compared to the previous year's 171.10 million. Earnings were 14.47 million, a decrease of -12.78%.